Evidence map›Paper›PMID 42126640›Full record

ArticleMycopathologia2026

Evaluation of the Clinical Characteristics and Survival of Pediatric Patients with Invasive Aspergillosis: A 12-year Retrospective Cohort Study.

Azer Karaman, Ali Bulent Cengiz, Kubra Aykac, Osman Oguz Demir, Dolunay Gülmez, Sevtap Arikan-Akdagli, Yasemin Ozsurekci

Abstract read
In one paragraph

Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Azer KaramanDepartment of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Ali Bulent CengizDepartment of Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Kubra AykacDepartment of Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Osman Oguz DemirDepartment of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Dolunay GülmezDepartment of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Sevtap Arikan-AkdagliDepartment of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Yasemin OzsurekciDepartment of Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Türkiye. yas.oguz99@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised children. Pediatric data are limited, and treatment guidelines often rely on adult studies. This study aimed to assess clinical characteristics and treatment outcomes of pediatric IA.

methodsWe conducted a retrospective cohort study of pediatric patients (0-18 years) diagnosed with IA at a tertiary center in Türkiye between 2010 and 2022. Data on demographics, underlying conditions, Aspergillus species, antifungal susceptibility, treatment regimens, and outcomes were analyzed. Survival analysis was performed using Kaplan-Meier curves.

resultsFifty-five children met criteria for proven (69%) or probable (31%) IA after excluding 22 possible cases. Median age was 8.6 years; mortality did not differ significantly by age, sex, or underlying condition. Hematologic malignancies were the most common comorbidity (35%). Aspergillus fumigatus was the predominant species (57%), and no antifungal resistance was detected. Classical risk factors; central venous catheter use (53%), neutropenia (51%), and recent chemotherapy (35%) were frequent but showed no association with mortality. Lung involvement was the most common presentation (71%), followed by sinus (31%) and central nervous system involvement (13%). Thirty-day mortality was 11%, 12-week mortality was 20% (11/55), and overall mortality reached 29%.

conclusionsPediatric IA remains associated with substantial morbidity and mortality, although outcomes in this cohort were more favorable than those reported in many prior pediatric series. No single clinical, microbiological, or radiological factor reliably predicted mortality, underscoring the complexity of risk stratification. Early diagnosis and timely antifungal therapy remain essential, and multicenter prospective studies are needed to optimize treatment approaches.

Indexed as

AspergillosisInvasive Pulmonary AspergillosisAdolescentAntifungal AgentsAspergillusChildChild, PreschoolFemaleHumansImmunocompromised HostInfantInfant, NewbornMaleRetrospective StudiesRisk FactorsSurvival AnalysisAntifungal AgentsAspergillus speciesChildrenInvasive aspergillosisTreatment outcome

Identifiers

PMID42126640
PMCPMC13171737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.